ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative1.88 B1.69 B1.69 B1.72 B1.95 B7.05 BRicerca e sviluppo1.72 B1.49 B1.74 B1.9 B2.14 B7.27 BReddito operativo2.31 B1.18 B2.66 B2.53 B2.72 B9.08 BProventi non operativi, Totale-782 M1.52 B-394 M2.08 B-553 M2.65 BOneri finanziari, al netto degli interessi capitalizzati747 M723 M694 M685 M653 M2.75 BProventi non operativi, esclusi gli oneri finanziari-1.53 B795 M-1.09 B1.4 B-1.21 B-104 MEntrate/uscite straordinarie——————Utile al lordo delle imposte781 M1.97 B1.57 B3.92 B8.98 B16.44 BQuota di utile-1 M—————Imposte155 M243 M136 M705 M181 M1.26 BInteressi di minoranza——————Altri proventi/oneri al netto delle imposte-131 M50 M23 M28 M-250 M-149 MUtile netto al lordo delle attività cessate627 M1.73 B1.43 B3.22 B1.33 B7.71 BAttività cessate——————Utile netto627 M1.73 B1.43 B3.22 B1.33 B7.71 BRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari627 M1.73 B1.43 B3.22 B1.33 B7.71 BUtile base per azione (EPS base)1.173.222.665.982.4714.33Utile diluito per azione (EPS diluito)1.173.22.655.932.4514.23Numero medio di azioni ordinarie in circolazione537 M538 M538 M538 M538 M2.15 BAzioni diluite in circolazione541 M541 M541 M542 M542 M2.17 BEBITDA3.71 B2.56 B4 B3.83 B3.85 B14.25 BEBIT2.31 B1.18 B2.66 B2.53 B2.72 B9.08 BCosto del fatturato3.11 B2.97 B3.01 B3.08 B2.98 B12.04 BAltri costi del venduto——————Ammortamento e svalutazione (liquidità)1.4 B1.39 B1.34 B1.31 B1.13 B5.17 B
Amgen Inc
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.
The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.